Bolt Biotherapeutics, Inc.
Public company- Headquarters
- REDWOOD CITY, California
- Ticker
- BOLT
- CIK
- 0001641281
WARN notices since 2024
1
First: May 14, 2024
Workers affected since 2024
38
Across 1 notice
Executive changes, last 12 months
1
1 appointment, 0 departures
Last event
Oct 23, 2026
Executive appointmentClass II director appointed: Sheila Gujrathi
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| Class II directorSheila Gujrathi | Oct 23, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- ACADIA PHARMACEUTICALS INC
Executive Vice President, Head of Research and Development departs: Elizabeth H.Z. Thompson, Ph.D.
- KYNTRA BIO, INC.
Class III director appointed: Andrew E. Singer, MBA
- BIOMARIN PHARMACEUTICAL INC
WARN notice: Novato, CA
- CORCEPT THERAPEUTICS INC
President of Corcept Endocrinology departs: Sean Maduck
- Executive appointment
Class II director appointed: Sheila Gujrathi
Sheila Gujrathi was named Class II director of Bolt Biotherapeutics, Inc., effective October 23, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 23, 2026Role: Class II director
Last verified Nov 8, 2026